Comparison of iron-sucrose with ferric carboxymaltose for treatment of postpartum iron deficiency anaemia
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20222461Keywords:
Anaemia, Iron-sucrose, Ferric carboxymaltose, Injectable iron therapyAbstract
Background: Anaemia is a major public health problem worldwide. Haemoglobin (Hb) cut-off in anaemia should be taken as 11 gm/dl in the first and third trimester and 10.5 gm/dl in the second trimester, and a post-partum Hb of 10.0 gm/dl. The aim of the study is to compare the efficacy of iron-sucrose versus ferric carboxymaltose (FCM) in the treatment of postpartum anaemia.
Methods: A prospective randomized interventional study of 132 post-partum females was conducted at a tertiary care hospital, over a 6-month period. Post-partum females delivered via normal vaginal delivery or caesarean section with Hb levels of above 7 gm/dl and below 9.9 gm/dl were randomized into 2 groups. Iron deficit calculated, in mg, according to Ganzoni’s formula. One group received intravenous FCM – 500 mg in 250 ml normal saline (NS) over 30 minutes and the other received intravenous iron sucrose - each ampoule containing 200 mg in 100 ml NS over 30 minutes up to a maximum dose of 1000 mg. Follow up done after 15 days, 4 weeks and 6 weeks. The data was tabulated and compared using statistical analysis.
Results: At a 4 and 6 weeks follow up, the mean rise in hemoglobin (Hb) of group A (1.4 g/dl) was significantly greater than that of group B (0.89 g/dl).
Conclusions: The study concludes that thought efficacy of drugs is similar, injection FCM shows a prompt rise in Hb, allows a higher dose to be dispensed in a single seating and is more significant in improving quality of life over a period of time even though it has a marginally higher cost.
References
World Health Organization. Prevalence of anemia among pregnant women. Global Health Observatory data repository/world health statistics. Available at: https://data.worldbank.org/indicator/sh.Prg.Anem. Accessed on 13 April 2022.
Koschorke A, Egbor M, Bhide A. Arias’ Practical Guide to High-Risk Pregnancy and Delivery; A South Asian Perspective; 5th edition. Hematological disorders and Red-cell alloimmunisation in pregnancy. Elsevier India. 2019;220-37.
Ministry of Health and Family Welfare, Government of India. India fact sheet. National Family Health Survey (NFHS-4) 2015-16. New Delhi, India: International Institute of Population Sciences. Available at: https://www.rchiips.org/nfhs/factsheet _NFHS_4.shtml. Accessed on 13 April 2022.
Kalaivani K, Ramachandran. Time trends in prevalence of anemia in pregnancy. Indian J Med Res. 2018;147(3):268-77.
Centre for Disease Control and Prevention. CDC criteria for anemia in children and childbearing-aged women. MMWR. 1989;38:400-4.
Royal College of Obstetricians and Gynaecologists. Blood transfusions in obstetrics. Green-top guideline no.47. 2007. Available at: https://www.rcog.org. uk/guidance/browse-all-guidance/green-top-guidelines/blood-transfusions-in-obstetrics-green-top-guideline-no-47/. Accessed on 13 April 2022.
Jose A, Mahey R, Sharma JB, Bhatla N, Saxena R, Kalaivani M, Kriplani A. Comparison of ferric Carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy- randomised controlled trial. BMC Pregnancy Childbirth. 2019;19(1):54.
Breymann C, Milman N, Mezzacasa A, Bernard R, Dudenhausen J. Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP). J Perinat Med. 2017;45(4):443-53.
Christoph P, Schuller C, Studer H, Irion O, De Tejada BM, Surbek D. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose. J Perinat Med. 2012;40(5):469-74.
